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iIschemic mitral regurgitation (IMR) is either acute
or chronic mitral insufficiency, caused by myocar-
dial ischemia and/or infarction. Chronic IMR is an
important cardiac disease that carries a grave prognosis
after myocardial infarction (MI). In some studies, it
has been shown to more than double the risk of
short-term mortality and increase the risk of develop-
ing congestive heart failure (1,2). Even mild IMR
diagnosed at the time of MI has been shown to confer
a significant mortality risk in long-term studies (3).
See page 220
Many aspects of IMR remain controversial. The
basic mechanism of IMR is commonly ascribed to
leaflet tethering as a result of the displacement of
papillary muscles (PMs) due to ventricular remod-
eling (4). Papillary muscle dysfunction seems cen-
tral to this mechanism, which was described by
Burch et al. (5) in 1963. While it is clear that the
PMs are not the sole players in IMR, they have
been the main suspect despite a number of controver-
sies concerning their contribution to IMR. Several
studies have suggested a strong role for PM in IMR.
Large-animal models have shown that both left ven-
tricular dilation and posterior PM infarction (PMI)
were necessary for the development of MR (6). A
retrospective study by Okayama et al. (7) in patients
with single-vessel coronary disease using cardiac mag-
netic resonance (CMR) to quantify PMI and MR
found an association between the presence of DE in
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Other lines of evidence, however, point to a
eaker or even reversed role for PM in IMR. Using
oppler strain imaging, PMI has been shown to
itigate rather than exacerbate the degree of IMR in
asal inferior infarction (8). Dog models of IMR
howed that when PM was selectively infarcted, it did
ot produce MR, whereas larger infarctions encom-
assing the PM and adjacent myocardium did pro-
uce MR (9). Another dog model showed that global
yocardial hypoperfusion but not PM hypoperfusion
ould produce MR (10). In the same study by
kayama et al. (7), patients with single vessel right
oronary artery disease as well as PMI had less MR
han patients who had no PMI. Another relatively
arge cohort of patients with ST-segment elevation
I who were imaged with echocardiography and
MRpost-infarction concluded that PMIwas common
nd was not necessarily associated with IMR (11).
In this issue of iJACC, Chinitz et al. (12) shed light
n these debates through a detailed, quantitative study
f the role of PMI and lateral wall infarction in IMR.
n a large prospective cohort of 153 patients with first
T-segment elevation MI without intrinsic mitral
alve disease, the investigators evaluated the incidence
nd severity of IMR as well as coronary and ventric-
lar anatomy. Echocardiography was used to quantify
R, angiography to identify culprit coronary lesions,
nd a high resolution DE-CMR sequence to define
he extent of PMI (partial vs. complete) and ventric-
lar infarction. The imaging studies were performed 3
o 4 weeks after MI. The results of these studies
howed that neither complete nor partial PMI neces-
arily led to the development of MR. However, the
mount of infarcted myocardium was significantly
ssociated with the development of MR. Not surpris-
ngly, the degree of PMI tracked with the overall
nfarct burden, where larger infarction was more likely
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236to be associated with complete PMI and any degree of
PMI was associated with larger left ventricular (LV)
infarction. The primary determinants of MR were re-
lated to the function of the adjacent LVmyocardium and
the overall geometry of the ventricle, PM, and the mitral
valve. The presence of large lateral wall infarction and
associated dysfunction were associated with the develop-
ment of MR even after multivariate analysis. Chinitz et
al. (12) clearly delineated that the infarcted LV myocar-
dium was the main determinant of IMR, not the PMs.
Let us then review the components of the mitral
apparatus and their respective dysfunction in IMR.
There is mitral leaflet tethering (13), and mitral
leaflet area increases over time but fails to compen-
sate adequately for tethering caused by ventricular
remodeling (14). There is mitral annulus dilation
and abnormal behavior (15). There is PMI and
dysfunction, and there is dysfunctional lateral ven-
tricular wall and ventricular remodeling. Despite
the popular focus on leaflet tethering and PM
dysfunction in IMR, the work of Chinitz et al. (12)
have shown more definitively than ever before that
the valves and the PM are merely accomplices in the
crime; the primary culprit for the development and
progression of chronic ischemic MR is the under-
lying ventricular infarction and adverse remodeling.
With this knowledge, how can we treat IMR
better? Surgical techniques have evolved to address
IMR at all of the components of the mitral apparatus.
Such methods have included restrictive annuloplasty,
chordal cutting to relieve tethering, PM modification,
and LV plication. Traditional mitral annuloplasty
rings have not been uniformly successful, and in some
studies they were associated with excess mortality
compared to revascularization procedures alone (16).
There is a large surgical clinical trial (17) ongoing tocome and prognostic implications cle late enhancemenmitral valve annuloplasty in treating patients with severe
IMR. As demonstrated by a sheep model of IMR, ring
annuloplasty does not address the underlying abnormal
leaflet tethering and PM dysfunction caused by lateral
wall infarction (18). Some innovative procedures directed
at addressing the mechanism of IMR are emerging as
viable options. One such example is the Coapsys device,
which reshapes the ventricle to improve mitral leaflet
coaptation and reduce IMR. Despite the unfortunate
demise of the manufacturer of the device, the results of
the randomized prospective multicentered study using
this device as compared to conventional indicated surgery
showed a mortality benefit at 2 years (19).
As the focus of the pathophysiology of chronic
IMR shifts to the lateral wall infarction and asso-
ciated reverse remodeling, we should consider treat-
ing these patients earlier in the course of the
disease. Using innovative therapies early after in-
farction such as ventricular restraint (20) and pap-
illary muscle reposition by polymer injection in the
adjacent myocardial wall (21), one might halt or slow
the adverse remodeling that would ultimately result in
severe IMR. Future work using computational models
that incorporate anatomic and tissue information ob-
tained from CMR might be able to predict future
development of significant IMR. The work of Chintz
et al. (12) has shown us the underlying cause of IMR
in a contemporary cohort of patients with ST-
segment elevation MI. Armed with this knowledge,
we need to continue to work on targeting effective
therapies early in the course of the disease that would
ultimately address the underlying mechanism.
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